Literature DB >> 22154974

Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda.

P M Namuwenge1, J K Mukonzo, N Kiwanuka, R Wanyenze, R Byaruhanga, K Bissell, R Zachariah.   

Abstract

Among HIV-infected adults attending non-governmental organization voluntary counseling and testing (VCT) sites in Uganda that provide a nine-month course of isoniazid preventive treatment (IPT), we report on loss to follow-up (LTFU) and its associated risk factors. The design was a retrospective cohort study of program data spanning a three year period (2006-2008). A total of 586 IPT patients were enrolled of whom 335 (57.1%) were females with a mean age of 34 years. Of those starting IPT, 341 (58.1%) were lost to follow-up, 197 (33.6%) completed IPT, 29 (4.9%) were discontinued and 19 (3.2%) died. The return rates at one, three, five and seven months were 78.0% (457), 62.1% (364), 52.9% (310) and 33.6% (197) respectively. Being less than 30 years of age, widowed, separated, or divorced were found to be associated with a higher risk of loss to follow-up. Sudden improvement in retention on IPT was observed between the years 2006 and 2007, although causes of the improvement are poorly understood hence the need for more research. At non-governmental VCT sites in Uganda, six out of ten individuals enrolled on IPT are lost to follow-up and efforts to reduce this attrition including systems strengthening might play a critical role in the success of IPT programs.
Copyright © 2011 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154974     DOI: 10.1016/j.trstmh.2011.10.015

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  13 in total

1.  Operational research training: the course and beyond.

Authors:  K Bissell; A D Harries; A J Reid; M Edginton; S G Hinderaker; S Satyanarayana; D A Enarson; R Zachariah
Journal:  Public Health Action       Date:  2012-09-21

2.  Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda.

Authors:  Khai Hoan Tram; Florence Mwangwa; Gabriel Chamie; Mucunguzi Atukunda; Asiphas Owaraganise; James Ayieko; Vivek Jain; Tamara D Clark; Dalsone Kwarisiima; Maya L Petersen; Moses R Kamya; Edwin D Charlebois; Diane V Havlir; Carina Marquez
Journal:  AIDS Care       Date:  2019-06-10

3.  Implementation of Isoniazid Preventive Therapy among People Living with HIV in Northwestern Nigeria: Completion Rate and Predictive Factors.

Authors:  Abiola Victor Adepoju; Chidubem L Ogbudebe; Olusola Adedeji Adejumo; Johnson Okolie; Jude O Inegbeboh
Journal:  J Glob Infect Dis       Date:  2020-05-22

4.  IPT during HIV treatment in Myanmar: high rates of coverage, completion and drug adherence.

Authors:  J Ousley; K P Soe; N T T Kyaw; R Anicete; P E Mon; H Lwin; T Win; S Cristofani; A Telnov; M Fernandez; I Ciglenecki
Journal:  Public Health Action       Date:  2018-03-21

5.  Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care.

Authors:  Khai Hoan Tram; Florence Mwangwa; Mucunguzi Atukunda; Asiphas Owaraganise; James Ayieko; Albert Plenty; Dalsone Kwariisima; Tamara D Clark; Maya L Petersen; Edwin D Charlebois; Moses R Kamya; Gabriel Chamie; Diane V Havlir; Carina Marquez
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-15       Impact factor: 3.731

6.  Routine implementation of isoniazid preventive therapy in HIV-infected patients in seven pilot sites in Zimbabwe.

Authors:  K C Takarinda; R C Choto; A D Harries; T Mutasa-Apollo; C Chakanyuka-Musanhu
Journal:  Public Health Action       Date:  2017-03-21

7.  Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives.

Authors:  Fred C Semitala; Allan Musinguzi; Jackie Ssemata; Fred Welishe; Juliet Nabunje; Jillian L Kadota; Christopher A Berger; Achilles Katamba; Noah Kiwanuka; Moses R Kamya; David Dowdy; Adithya Cattamanchi; Anne R Katahoire
Journal:  Implement Sci Commun       Date:  2021-06-30

8.  Incidence and determinants of tuberculosis among adults initiating antiretroviral therapy--Mozambique, 2004-2008.

Authors:  Andrew F Auld; Francisco Mbofana; Ray W Shiraishi; Charity Alfredo; Mauro Sanchez; Tedd V Ellerbrock; Lisa J Nelson
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

9.  Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania.

Authors:  Grace A Shayo; Candida Moshiro; Said Aboud; Muhammad Bakari; Ferdinand M Mugusi
Journal:  BMC Infect Dis       Date:  2015-08-26       Impact factor: 3.090

10.  Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.

Authors:  D Thindwa; P MacPherson; A T Choko; M Khundi; R Sambakunsi; L G Ngwira; T Kalua; E L Webb; E L Corbett
Journal:  Int J Tuberc Lung Dis       Date:  2018-03-01       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.